NCT05590221 2024-01-08Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell LymphomaPeking University Cancer Hospital & InstitutePhase 2 Unknown20 enrolled
NCT03355859 2019-07-12Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaRuijin HospitalPhase 1 Unknown10 enrolled